Literature DB >> 10832100

Apolipoprotein-mediated cellular cholesterol/phospholipid efflux and plasma high density lipoprotein level in mice.

M Tsujita1, S Tomimoto, K Okumura-Noji, M Okazaki, S Yokoyama.   

Abstract

Helical apolipoprotein(apo)s generate pre-beta-high density lipoprotein (HDL) by removing cellular cholesterol and phospholipid upon the interaction with cells. To investigate its physiological relevance, we studied the effect of an in vitro inhibitor of this reaction, probucol, in mice on the cell-apo interaction and plasma HDL levels. Plasma HDL severely dropped in a few days with probucol-containing chow while low density protein decreased more mildly over a few weeks. The peritoneal macrophages were assayed for apoA-I binding, apoA-I-mediated release of cellular cholesterol and phospholipid and the reduction by apoA-I of the ACAT-available intracellular cholesterol pool. All of these parameters were strongly suppressed in the probucol-fed mice. In contrast, the mRNA levels of the potential regulatory proteins of the HDL level such as apoA-I, apoE, LCAT, PLTP, SRB1 and ABC1 did not change with probucol. The fractional clearance rate of plasma HDL-cholesteryl ester was uninfluenced by probucol, but that of the HDL-apoprotein was slightly increased. No measurable CETP activity was detected either in the control or probucol-fed mice plasma. The change in these functional parameters is consistent with that observed in the Tangier disease patients. We thus concluded that generation of HDL by apo-cell interaction is a major source of plasma HDL in mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10832100     DOI: 10.1016/s1388-1981(00)00061-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

Review 1.  Reconstituted Discoidal High-Density Lipoproteins: Bioinspired Nanodiscs with Many Unexpected Applications.

Authors:  Maki Tsujita; Anna Wolska; Daniel A P Gutmann; Alan T Remaley
Journal:  Curr Atheroscler Rep       Date:  2018-11-05       Impact factor: 5.113

2.  Abnormal lipoprotein metabolism and reversible female infertility in HDL receptor (SR-BI)-deficient mice.

Authors:  H E Miettinen; H Rayburn; M Krieger
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

3.  The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1.

Authors:  Richard J Jones; Dongmin Gu; Chad C Bjorklund; Isere Kuiatse; Alan T Remaley; Tarig Bashir; Veronique Vreys; Robert Z Orlowski
Journal:  J Pharmacol Exp Ther       Date:  2013-07-02       Impact factor: 4.030

4.  Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.

Authors:  Tomoyuki Nishimoto; Yuichiro Amano; Ryuichi Tozawa; Eiichiro Ishikawa; Yoshimi Imura; Hidefumi Yukimasa; Yasuo Sugiyama
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

5.  Pharmacological inhibition of ABCA1 degradation increases HDL biogenesis and exhibits antiatherogenesis.

Authors:  Reijiro Arakawa; Maki Tsujita; Noriyuki Iwamoto; Chisato Ito-Ohsumi; Rui Lu; Chen-Ai Wu; Kenji Shimizu; Tomoji Aotsuka; Hashime Kanazawa; Sumiko Abe-Dohmae; Shinji Yokoyama
Journal:  J Lipid Res       Date:  2009-05-20       Impact factor: 5.922

6.  Exposure to High Glucose Concentration Decreases Cell Surface ABCA1 and HDL Biogenesis in Hepatocytes.

Authors:  Maki Tsujita; Mohammad Anwar Hossain; Rui Lu; Tomoe Tsuboi; Kuniko Okumura-Noji; Shinji Yokoyama
Journal:  J Atheroscler Thromb       Date:  2017-04-19       Impact factor: 4.928

7.  Selective Correction of Genotype Yield by Probucol in HDL-Deficient Mice Propagation.

Authors:  Maki Tsujita; Nobukatsu Akita; Tomo Yokota; Fumihiko Kobayashi; Shinji Yokoyama
Journal:  J Atheroscler Thromb       Date:  2019-05-14       Impact factor: 4.928

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.